tirezepatide vs semaglutide POTD: Wegovy and Ozempic — Maimonides Emergency Medicine Residency GLP-1 Weight Loss Injections |

among them, the rounded-down age of the participants was 54 years, where 59% were females and the average body weight was 108.7 kg, and the average BMI was 37.9

In the dermato-aesthetic field, cycles of GSH IV combined with vitamin C show results on skin tone and reduction of hyperpigmentation, albeit in the absence of formal dedicated RCTs. Protocols and outcome assessment Currently used protocols for NAD IV involve doses of 250-500 mg per session, with slow infusions (2-6 hours) and weekly frequency for 4-8 weeks, followed by monthly maintenance

With expert dietitian guidance and strategies, the Healthy GLP-1 Journey will help you achieve lasting weight loss

Wegovy was FDA-approved in 2021 as a weight loss drug

Clinical trials have consistently shown that oral semaglutide produces weight-loss results comparable to the injectable version